Two Sigma Investments, LP Galectin Therapeutics Inc Transaction History

Two Sigma Investments, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $117,954 - $154,665	-60,181 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.24 - $2.87 $137,542 - $176,226	-61,403 Reduced 50.5%	60,181 $135,000
Q3 2020 Nov 16, 2020	BUY	$2.53 - $3.64 $114,846 - $165,234	45,394 Added 59.58%	121,584 $325,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $98,368 - $186,662	59,258 Added 349.98%	76,190 $233,000
Q1 2020 May 15, 2020	BUY	$1.51 - $3.0 $25,567 - $50,796	16,932 New	16,932 $33,000

9.38M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $158M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.